IU Health University Hospital
Indianapolis, Indiana, 46202, United States
Location status: Recruiting
Location contact
Muhammad Y Jan
PRINCIPAL_INVESTIGATOR
NCT Number: NCT05717842
The purpose of the study is to determine how much a persons kidney function recovers after receiving a simultaneous liver kidney transplant. The investigators will be contacting patients with kidney dysfunction with estimated GFR between 25 and 40 (not on dialysis treatment) who are listed to receive a simultaneous liver kidney (SLK) transplant to look at this function recovery. The investigators hope to develop a criteria based on GFR measurement, kidney function calculations from native kidneys vs transplanted kidney and compare the contributions, and correlate with estimated GFR on basic metabolic panel (BMP: a blood test) to predict higher chances of recovery of native kidney function.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Indianapolis, Indiana, 46202, United States
Location status: Recruiting
Muhammad Y Jan
PRINCIPAL_INVESTIGATOR
Study design
Study will be a pilot longitudinal prospective study. SLK transplant listed patients will be recruited from the outpatient Liver Kidney Transplant Clinic at Medical Diagnostic Clinic (MDC) as well as inpatients admitted to IU University Hospital. Listing status for SLK transplant will be confirmed and patients will be scheduled for a Mag3 nuclear medicine scan at IU University Department of Nuclear medicine. For study purposes, this scan will be done pre and post-transplant to compare the results.
Methods:
Inclusion/Exclusion criteria:
Inclusion:
Exclusion criteria
Data collection: Data collection will be done in RedCap©️ These data forms will incorporate a comprehensive list of variables:
Participants will be informed about the results of their studies. Participation will be voluntary. Compensation will be provided once in the form of $25 gift card that will be provided upon completing participation for the nuclear medicine scan 10 months after patients receive their SLK transplant. Patients and their insurance will not be charged and the testing will be invoiced to the study grant.
Provisions for post-study care No provision will be provided for care regarding incidental findings on the nuclear medicine scan. They will be given information regarding referral to seeking appropriate care. No expenses will be reimbursed for this care.
Participant timeline:
Enrollment of participants will be done starting February 2023 and completed by December 2023
Statistical Analyses:
Sample size:
Estimated number of participants is determined by participants listed for SLK transplant. An estimated 15 participants are planned to be recruited. As this is a pilot study, all participants at IU will be asked to participate with a future goal of a multi-center study.
Plans for assessment and collection of outcomes:
Data will be collected in IU RedCap registry, which is a secure platform. Data will be entered in Redcap, coded, secured, and stored. Any raw data collection (source documents) will be kept in a locked cabinet in a locked office. Data will be processed with SPSS data management software.
Confidentiality Information about potential and enrolled participants will be collected, shared, and maintained in a manner that protects confidentiality before, during, and after the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Mercaptoacetyltriglycine 3 (Mag 3) Nuclear Medicine Scan
Time frame: up to 100 weeks
To determine split kidney function with a Mag3 (Mercaptoacetyltriglycine 3) nuclear medicine renal scan as part of the study procedures.
Time frame: up to 100 weeks
This includes standard testing performed at our center prior to SLK transplant which are standard of care. This will include measurement of eGFR by Cystatin C.
Contact information is provided by the study sponsor or research team.
Indiana University
Other
Simultaneous Prospective Kidney Transplant Assessment in Combined Liver Kidney
Acronym: RECOVERY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04626167
Bladder Absence, Bladder Dysfunction
Rochester, Minnesota, United States
View Trial DetailsNCT04182607
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Dallas, Texas, United States
View Trial DetailsNCT04390724
Adenocarcinoma, Adult Primary Liver Cancer
Jacksonville, Florida, United States
View Trial DetailsNCT03691220
Transplant
Los Angeles, California, United States
View Trial Details